Neurology
4 drugs are in development for Fabry Disease.
- Companies
- 4
- Clinical trials
- 24
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Fabry Disease pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| elfabrio | Protalix BioTherapeutics, Inc. (PLX) |
Preclinical(1)
| Drug | Company |
|---|---|
| sig-007 | Sigilon Therapeutics, Inc. (SGTX) |
Phase 1/Phase 2(2)
| Drug | Company |
|---|---|
| amt-191 | uniQure N.V. (QURE) |
| isaralgagene civaparvovec | SANGAMO THERAPEUTICS, INC (SGMOQ) |
About this indication
Fabry Disease context
Neurology·MeSH: Fabry Disease (D000795)
Also known as: Anderson Fabry Disease, Angiokeratoma Corporis Diffusum, Angiokeratoma Diffuse, Deficiency, Ceramide Trihexosidase, Deficiency, GLA, Deficiency, alpha-Galactosidase A, Diffuse Angiokeratoma, Fabry's Disease, Lipidosis, Hereditary Dystopic, alpha Galactosidase A Deficiency Disease
Incidence
0.2 / 100K/yr
Frequently asked questions
How many drugs are in development for Fabry Disease?
BioSniper tracks 4 drugs in development for Fabry Disease across 4 companies.
How many clinical trials target Fabry Disease?
There are 24 clinical trials targeting Fabry Disease tracked by BioSniper.